| 商品名称 | Clopidogrel BMS |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Stroke;Peripheral Vascular Diseases;Myocardial Infarction;Acute Coronary Syndrome |
|---|
| 通用名/非专利名称 | clopidogrel |
|---|
| 活性成分 | clopidogrel (as hydrogen sulfate) |
|---|
| 产品号 | EMEA/H/C/000974 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Withdrawn |
|---|
| ATC编码 | B01AC04 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2008/07/16 |
|---|
| 上市许可开发者/申请人/持有人 | Bristol-Myers Squibb Pharma EEIG |
|---|
| 人用药物治疗学分组 | Antithrombotic agents |
|---|
| 兽用药物治疗学分组 | |
|---|
| 欧盟委员会决定日期 | 2009/10/26 |
|---|
| 修订号 | 3 |
|---|
| 治疗适应症 | Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: - Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. - Patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2009/10/26 |
|---|
| 最后更新日期 | 2010/01/26 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/clopidogrel-bms-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-bms |
|---|